Wednesday, July 18, 2018
Company News: Page (1) of 1 - 06/12/18 Email this story to a friend. email article Print this page (Article printing at page facebook
FIT Biotech Oy: First EHVA clinical trial authorization granted for testing FIT-06

(June 12, 2018)

FIT Biotech Oy 

Company release 12.6.2018 at 8:30 AM EET

First EHVA clinical trial authorization granted for testing FIT-06

FIT Biotech Oy ("Company", FITBIO: FN Finland) today announced that the Swiss medical authorities have granted the European HIV Vaccine Alliance (EHVA) the permission to start a phase I/II clinical trial. In this trial, FIT Biotech's HIV vaccine candidate FIT-06 is a part of a regimen whose safety and efficacy are tested with participants living with HIV. This trial is part of a multicentric trial with study sites in six European countries, sponsored by INSERM-ANRS (French National Institute of Health and Medical Research) and is expected to start in June 2018.

Worldwide, almost 37 million people are living with HIV and approximately 2 million new infections occur every year. The Company's clinical stage candidate FIT-06 aims to address the problems of standard therapies that include restricted access to medication, continuous patient retention in therapy, social stigma and potentially serious side effects. There is a need to provide a safer and more cost-effective alternative to current HIV therapies, and the FIT-06 vaccine is part of the EHVA arsenal to represent an important element in this strategy.

CEO Erkki Pekkarinen comments: "We are proud to be a part of the EHVA consortium and look very much forward to the start of this clinical trial. Our vaccine candidate FIT-06 is the prime vaccine component in this trial and results will be very important not only to us, but first and foremost to patients, who we aim to provide an improved alternative to control HIV through immunotherapy rather than chemical drugs."

Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: [email protected]

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTUŽ (Gene Transport Unit) vector technology for new-generation medical treatments. GTUŽ is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTUŽ technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

About EHVA
The European HIV Alliance (EHVA) is a five-year project funded by the European Union's Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. The international alliance, which includes academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America, will work to discover and progress novel vaccine candidates through the clinic (

Nasdaq Helsinki
Principal media

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution

  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally -
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines